| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01428284 | Healthy | Drug: Canagliflozin/Probenecid | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2011-08-01 | 2012-02-16 |
| NCT01029782 | Cellulitis | Drug: IV cefazolin plus oral probenecid and placebo cephalexin|Drug: Oral cephalexin and saline IV plus probenecid placebo | Kelowna General Hospital|Canadian Society of Hospital Pharmacists|Capital Health, Canada|Interior Health Authority, Canada | Phase 2 | 2010-05-01 | 2015-01-13 |
| NCT01814319 | Systolic Heart Failure | Drug: Probenecid 1 gr oral twice daily|Drug: Placebo | University of Cincinnati | Phase 2 | 2013-03-01 | 2015-08-24 |
| NCT00842400 | Obesity | Drug: Metformin, VI-0521, Sitagliptan, Probenecid | VIVUS, Inc. | Phase 1 | 2009-02-01 | 2010-01-20 |
| NCT02243631 | Calcium Pyrophosphate Deposition Disease | Drug: Probenecid | VA Office of Research and Development | Early Phase 1 | 2014-10-01 | 2017-01-04 |
| NCT01937026 | Healthy Volunteers | Drug: Baricitinib|Drug: Probenecid | Eli Lilly and Company | Phase 1 | 2013-09-01 | 2013-12-03 |
| NCT00000670 | HIV Infections | Drug: Probenecid|Drug: Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID) | | | 2012-03-15 |
| NCT00000706 | HIV Infections | Drug: Quinine sulfate|Drug: Probenecid|Drug: Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID) | | | 2012-03-15 |
| NCT00024245 | Unspecified Adult Solid Tumor, Protocol Specific | Drug: pralatrexate|Drug: probenecid | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Phase 1 | 2001-05-01 | 2013-06-25 |
| NCT01907373 | Drug Interaction of Olmesartan in Healthy Chinese Volunteers | Drug: olmesartan medoxomil|Drug: olmesartan medoxomil+probenecid | Central South University | Phase 4 | 2009-08-01 | 2013-07-24 |
| NCT00610532 | Epilepsy | Drug: phenytoin|Drug: phenytoin and probenecid | Jim McAuley|Ohio State University | Phase 4 | 2006-03-01 | 2013-05-13 |
| NCT01634100 | Healthy | Drug: Probenecid|Drug: Rifampicin|Drug: Empagliflozin|Drug: Empagliflozin|Drug: Rifampicin|Drug: Probenecid|Drug: Empagliflozin (BI 10773) | Boehringer Ingelheim | Phase 1 | 2012-06-01 | 2014-06-27 |
| NCT00304434 | Influenza | Drug: Oseltamivir|Drug: Probenecid | VA Office of Research and Development|Brooke Army Medical Center|National Institutes of Health (NIH) | Phase 4 | 2005-02-01 | 2009-09-21 |
| NCT00323219 | Cellulitis | Drug: Cefazolin and Moxifloxacin | University of British Columbia | Phase 3 | 2004-01-01 | 2012-02-06 |
| NCT00690014 | Kidney Disease | Drug: probenecid | University of Maryland|National Institutes of Health (NIH) | | 2007-08-01 | 2008-06-03 |
| NCT00439530 | Avian Influenza A Virus | Drug: oseltamivir|Drug: probenecid | Mahidol University|National Institute of Allergy and Infectious Diseases (NIAID)|Southeast Asia Influenza Clinical Research Network | Phase 1 | 2006-11-01 | 2009-07-24 |
| NCT01322009 | Pediatric Traumatic Brain Injury | Drug: Probenecid and N-acetyl cysteine|Drug: Placebo | University of Pittsburgh|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1|Phase 2 | 2011-03-01 | 2016-07-01 |
| NCT01816646 | Blood And Marrow Transplantation | Drug: Cidofovir|Drug: Probenecid | M.D. Anderson Cancer Center|Gilead Sciences | Phase 1 | 2013-09-01 | 2016-12-02 |
| NCT01021020 | Healthy | Drug: Colchicine|Drug: Colchicine|Drug: Colchicine/Probenecid | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2007-09-01 | 2009-12-01 |
| NCT00002437 | Cytomegalovirus Retinitis|HIV Infections | Drug: Cidofovir|Drug: Probenecid | Gilead Sciences|NIH AIDS Clinical Trials Information Service | Phase 2 | | 2005-06-23 |
